The annual demand exceeds 450000 units, and this type of medical equipment is on the rise!

The prevalence rate of COPD in people aged 40 and above is 13.6% in China, with nearly 100 million people suffering from the disease. More than 1 million people die of COPD in China every year, accounting for one third of the global total, with an average of 2.5 people dying every minute, and the mortality rate and disease burden far higher than the world average.

Compared with hypertension and diabetes, the public awareness of COPD is very low. Due to multiple factors such as inadequate diagnosis and treatment, non-standard diagnosis and treatment, delay in early intervention, etc., COPD has gradually become the third most lethal disease in China.

The State Council issues a document, new indicators for grassroots medical services!

Therefore, as early as in the Healthy China Action (2019-2030) issued by The State Council, it has been mentioned that the prevention and treatment of chronic respiratory diseases should be implemented, the first diagnosis of high-risk groups should be explored to measure lung function, and the physical examination of people aged 40 and above should detect lung function.

The health management of patients with chronic COPD should be strengthened, and the ability of lung function examination in primary medical and health institutions should be improved. By 2030, the death rate from chronic respiratory diseases among people aged 70 and below should be reduced to 8.1 per 100,000 or less.

Recently, Zhang Wei, a deputy to the National People’s Congress and president of the First Affiliated Hospital of Nanchang University, proposed to include COPD into basic public health services and strengthen the construction of respiratory disease system in grassroots health institutions.

Obviously, whether COPD is included in the basic public health project or the requirements of the Healthy China Action, higher requirements are put forward for the diagnosis and treatment of COPD in 978,000 primary medical institutions across the country.

In fact, COPD is a common, preventable and treatable disease, but because patients with COPD often have no obvious symptoms in the early stages, pulmonary function tests are currently the recognized objective indicator for detecting airflow limitation, which is why they are called the “gold standard” for COPD diagnosis.

However, according to the current investigation, many basic village doctors’ rooms or township health centers lack relevant instruments for lung function diagnosis and treatment, including the corresponding diagnosis and treatment site, funds, local people’s disease cognition and health concept and other aspects also have certain weaknesses, which is not conducive to early diagnosis and treatment of COPD lung disease.

However, as the country attaches more importance to such chronic diseases and the basic public health service projects are continuously improved, the demand for lung function examination equipment of various primary medical institutions will be further increased in the next 3-5 years, so as to improve the capacity of screening and intervention, health management and disease monitoring for chronic respiratory diseases, and reach the ultimate goal of the country by 2030. 

In recent years, pulmonary function apparatus can be said to be one of the most rapidly developing industries in the field of respiratory diagnosis.

Before 2019, the domestic pulmonary function apparatus market was still dominated by foreign brands, but after 2019, the number of Chinese pulmonary function apparatus players increased sharply.

According to the statistics of the NMPA, the number of domestic lung function instrument products has reached 23, including Contecmed, M&B, Sonmol, MeHow and other enterprises.

On March 6th, the key points of the Healthy China Action for 2023 were issued, and the medical and health work in 2023 was also fully launched. A new round of medical equipment allocation boom is coming.

China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls fee

Source：Medical Device Distributors Union

Shanghai Sonmol Medical Devices Co.,Ltd.